Irvine, CA (PRWEB) November 26, 2012
VelaShape®, the world’s first and only FDA approved, non-surgical alternative clinically proven to temporarily reduce the appearance of cellulite while smoothing and shaping problem areas, and Rickie Freeman, creator of fashion label Teri Jon®, have teamed to create the Little Vela Dress luxury sweepstakes. It offers women a chance to experience a fairy tale styling and beauty treatments that are usually reserved for Hollywood’s elite. The campaign was designed to empower women to be confident about their bodies especially when wearing that little black dress that is so prevalent during the holiday season.
The contest runs through Sunday, November 30, 2012. One lucky grand prize winner will be selected at the end of the contest to win a series of four customized VelaShape® treatments with a premier physician. The winner will also be awarded a roundtrip to New York City to meet Rickie Freeman of Teri Jon® in her glam showroom where she will receive a customized Little Vela Dress fitted just for her. Finally, a Hollywood makeover – hair and makeup – done by a celebrity stylist that will conclude with a professional photo shoot. The total prize package is valued at $5,000. Ten lucky runners-up will also be chosen at random to win a $100 gift card to shop at http://www.terijon.com. All winners will be announced Monday, December 1.
“The Little Black Dress is so versatile, it can take you from a power breakfast through the day and into a night on the town with style,” says Rickie. “The Little Black Dress is a timeless style that appeals across many generations. Today the LBD is often cut shorter and fits tighter. VelaShape® can help women love their bodies even more.”
It’s estimated that anywhere from 85 percent to 98 percent of women over the age of 16 have cellulite. A recent survey of American women 25 and up identified their tummy bulge (70 percent) as their #1 concern followed by muffin top (55 percent) and cellulite (45 percent)[i]. VelaShape is the non-surgical alternative that’s clinically proven to temporarily reduce the appearance of cellulite while smoothing and shaping the areas that diet and exercise can’t quite fix. With over 500,000,000 million media impressions, over 10,000 procedures performed every day and over 40 published clinical studies, VelaShape® remains the trusted technology for cellulite and non-surgical body shaping by physicians, beauty experts and millions of patients worldwide.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology, real science and real results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company’s aspiration and commitment to innovation expands Syneron’s offering beyond medical device into the largest in-demand applications in beauty - skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at http://www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing “believes,” “anticipates,” “plans,” “expects,” “may,” “will,” “would,” “intends,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.’s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.’s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.’s views as of any date after the date of this document.